Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Aspen Neuroscience Secures $115M Series C Funding
Series CVenture Capital

Aspen Neuroscience Secures $115M Series C Funding

•November 20, 2025
•Nov 20, 2025
0

Participants

Aspen Neuroscience

Aspen Neuroscience

company

Axon

Axon

investor

OrbiMed

OrbiMed

investor

ARCH Venture Partners

ARCH Venture Partners

investor

Lifeforce Capital

Lifeforce Capital

investor

Frazier Life Sciences

Frazier Life Sciences

investor

BAM

BAM

investor

Lyfe Capital

Lyfe Capital

investor

Cormorant

Cormorant

investor

Prebys Foundation

Prebys Foundation

investor

Revelation Partners

Revelation Partners

investor

Medical Excellence Capital

Medical Excellence Capital

investor

S32

S32

investor

Why It Matters

The infusion of $115 million accelerates development of a potentially disease‑modifying Parkinson’s treatment, positioning Aspen as a frontrunner in personalized regenerative therapy and attracting further biotech investment in the neuro‑degeneration space.

Deal Summary

Aspen Neuroscience announced the closing of a $115 million Series C round to advance its autologous regenerative therapies for Parkinson's disease. The round was co‑led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences and Revelation Partners, with participation from existing and new investors.

0

Comments

Want to join the conversation?

Loading comments...